WALTHAM, Mass.--(BUSINESS WIRE)--OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today reported financial results for the quarter ended June 30, 2007 and provided an update on its oncology and ophthalmology drug development programs.
